Related by context. All words. (Click for frequent words.) 68 cisplatin resistant 68 Epidermal Growth Factor Receptor 67 Kit CD# positive 67 5 HT2A serotonin 67 chimeric monoclonal antibody 66 hypereosinophilic syndrome 66 receptor tyrosine kinase 66 tyrosine kinase receptor 66 CYT# potent vascular disrupting 66 CYP#A# CYP#D# 66 metastatic neuroendocrine tumors 65 EGFR receptor 65 Factor Receptor 65 IMiDs ® compound 65 Upregulation 65 Cytotoxic T 65 hepatoma 65 gastrointestinal stromal tumors GISTs 65 alpha folate receptor 65 EGFR HER2 65 Cathepsin B 65 kidney urologic 65 BRAF V#E 65 metastatic colorectal 64 receptor tyrosine kinase inhibitor 64 NSCLC tumors 64 LHRH receptor positive 64 refractory chronic lymphocytic 64 Aplidin R 64 IGF IR 64 Gleevec resistant 64 oropharyngeal candidiasis OPC 64 myelofibrosis polycythemia vera 64 mTOR mammalian target 64 Leukemias 64 K ras mutations 64 pan histone deacetylase 64 T#I [002] 64 thalidomide Thalomid 64 intratumoral injection 64 IgG1 monoclonal antibody 63 histone deacetylase inhibitor 63 metastatic malignant 63 biliary tract cancer 63 colon carcinoma 63 targeted antifolate 63 accumulate preferentially 63 malignant ovarian 63 lung pancreatic 63 papillary renal cell carcinoma 63 MAGE A3 ASCI 63 cyclin dependent kinase CDK 63 PI3K Akt 63 IMiDs R 63 gefitinib Iressa 63 activating mutations 63 Squamous 63 protein tyrosine phosphatase 1B 63 essential thrombocythemia ET 63 apoptosis proteins 63 interferon beta 1a infertility 63 HuMax 63 Peginterferon alfa 2b 63 c KIT 63 Enzastaurin 63 ovarian breast 62 Fibroblast 62 Oncogenic 62 metastatic carcinoma 62 selective modulator 62 Janus kinase 62 D aspartate NMDA receptor 62 NS5b 62 monoclonal antibody IgG1 Mab 62 serine threonine kinase 62 lymphangiogenesis 62 HER2 receptor 62 replicon 62 chronic eosinophilic leukemia 62 mda 7 62 HER2 overexpression 62 mutated K ras 62 prostate carcinoma 62 cortisol synthesis 62 hypermethylated 62 vinca alkaloid 62 complement inhibitor eculizumab 62 myelodysplastic myeloproliferative diseases 62 Immunohistochemical staining 62 pan HDAC inhibitor 62 Immunotherapeutic 62 urothelial carcinoma 62 p# mitogen activated 62 CDK cyclin dependent 62 erlotinib Tarceva ® 62 surgically resected 62 epithelial tumors 62 Tumor Necrosis Factor 62 Papillary 62 BRCA1 BRCA2 62 androgen receptor AR 62 VEGFR2 inhibitor 62 tumor xenograft models 62 ABCB1 62 poly ADP ribose polymerase 62 pancreatic adenocarcinoma 62 IAP inhibitor 62 FLT3 62 ZACTIMA 62 NF kB pathway 62 polycythemia vera PV 62 BiTE ® 62 M2 subunit 61 MCSP respectively 61 neuroendocrine cancers 61 multiple myeloma MM 61 nonmetastatic 61 COPEGUS R 61 CD# CD# 61 colorectal carcinoma 61 imatinib resistant 61 LRP5 61 node metastases 61 haematologic malignancies 61 tumor necrosis 61 metastatic GIST 61 GW# [003] 61 Hormone Refractory Prostate Cancer 61 TO AVOID PREGNANCY WHILE 61 telomerase reverse transcriptase 61 targeting CD# 61 experimental autoimmune encephalomyelitis 61 sunitinib Sutent ® 61 DNA methyltransferase inhibitors 61 anti CD3 61 irreversible inhibitor 61 p# biomarker 61 novel VDA molecule 61 Bruton tyrosine kinase 61 adipogenic 61 EGF receptor 61 lymphomas leukemias 61 cyclin dependent kinase inhibitor 61 XL# inhibits 61 selectively inhibited 61 Soft Tissue Sarcoma 61 systemic anaplastic large 61 CYC# 61 III EGFRvIII 61 recurrent NSCLC 61 Interferon gamma 61 molecule epidermal 61 EGFR mutant 61 KRAS mutant 61 tumors GIST 61 inhibitor COX 61 mediated apoptosis 61 cell adhesion molecule 61 subependymal giant cell 61 ERK1 2 61 investigational monoclonal antibody 61 Aplidin 61 alefacept 61 MKC# MT 61 potent antiproliferative 61 orally administered inhibitor 61 basal cell carcinoma BCC 61 histone deacetylase HDAC inhibitor 61 familial amyloidotic polyneuropathy FAP 61 HLA DR4 60 soluble tumor necrosis 60 antiangiogenic agent 60 Monoclonal antibody 60 imatinib Gleevec ® 60 recurrent glioblastoma multiforme 60 Aurora Kinase 60 Mg Usa 60 lymphoid malignancies 60 pancreatic prostate 60 pathophysiological effects 60 tumorigenicity 60 bevacizumab Avastin R 60 Advanced Renal Cell 60 CD# expressing 60 Kinase Inhibitor 60 ErbB1 60 vaginal candidiasis 60 Hepatocellular Carcinoma HCC 60 K RAS 60 p# deficient 60 BRAF V#E mutation 60 dasatinib Sprycel 60 peptidic compound 60 fluoropyrimidine 60 MAPK pathway 60 macrophage colony stimulating 60 HER2 neu 60 Cutaneous T 60 trastuzumab Herceptin ® 60 NKX#.# 60 acute myeloid 60 pheochromocytoma 60 NFkB 60 Virulizin ® 60 advanced metastatic renal 60 HBeAg negative 60 Protein Kinase C 60 interleukin IL -# 60 Lymphocytic 60 Alfacell proprietary ribonuclease 60 unresectable locally advanced 60 colorectal bladder 60 anaplastic lymphoma kinase ALK 60 dasatinib Sprycel ® 60 advanced hepatocellular carcinoma 60 whose tumors overexpress 60 hemostasis analyzers 60 benign neoplasms 60 EGFR tyrosine kinase inhibitors 60 interferon IFN 60 cervical lymph nodes 60 PKC# 60 MDR1 60 Polymerase Inhibitor 60 methyl D aspartate 60 selective kinase inhibitor 60 Moraxella catarrhalis 60 tissue transglutaminase 60 potently inhibited 60 Ribavirin causes 60 potent cytotoxic 60 bronchoalveolar lavage fluid 60 caveolin 1 60 FGFR3 60 Pharmacokinetics PK 60 galiximab 60 synovial tissue 60 Aurora kinase 60 lung carcinomas 60 carcinoma HCC 60 TNF α 60 PDGFR 60 receptors EGFR 60 microtubule inhibitor 60 FOLFOX6 60 metastatic breast 60 E7 proteins 60 nucleoside analog 60 Aflibercept 60 DU# [002] 60 RRM1 60 PEGylated Fab fragment 60 urothelial 60 multi kinase inhibitor 60 EGFr 60 IMiDs ® 60 mRCC 60 immunostimulatory 60 Adjuvant Treatment 60 Estrogen Receptor 60 Endometrial 60 Immunohistochemical analysis 60 Tyrosine Kinase Inhibitor 60 PI3K/Akt pathway inhibitor 60 cutaneous T 60 histological subtype 60 metastatic colorectal carcinoma 60 HLA DR2 60 KRAS wild 60 promoter hypermethylation 59 HER2 ErbB2 59 nonnucleoside reverse transcriptase inhibitors 59 relapsed MM 59 factor HGF 59 anastrazole 59 CD# + [001] 59 upregulating 59 Trastuzumab 59 KRAS mutations 59 HER2 HER2 59 serine protease 59 histone deacetylation 59 oncolytic virus therapies 59 vincristine doxorubicin 59 antiproliferative effects 59 Angiotensin Converting Enzyme 59 anthracycline chemotherapy 59 Oral Fingolimod 59 soluble receptor 59 virus AAV 59 osteosarcomas 59 cisplatin gemcitabine 59 metastatic gastric 59 Sezary syndrome 59 NeoLipid R 59 VEGF induced 59 malignant ascites 59 monocytes macrophages 59 antibody MAb 59 Macrophage 59 targeted radiotherapeutic 59 Vidaza ® 59 immunohistochemical staining 59 Cloretazine R 59 ERBB2 59 inverse agonist 59 ErbB2 positive 59 effector function 59 HDACi 59 HER2 expression 59 induces apoptosis 59 factor TNF 59 Hurthle cell 59 Tarceva TM 59 IL #R 59 V#F mutation 59 TTR gene 59 Nat Clin Pract 59 cyclooxygenase 59 CCR9 59 selectively binds 59 syngeneic 59 Waldenstrom macroglobulinemia 59 advanced pancreatic neuroendocrine 59 cytostatic 59 SPRYCEL ® 59 phosphatidylinositol 3 59 cetuximab Erbitux R 59 operable breast cancer 59 brivanib 59 TRAIL R2 59 Neoadjuvant 59 OncoVex 59 Degarelix 59 NMIBC 59 E#F# 59 Granulocyte Colony Stimulating Factor 59 downstream effector 59 pegylated liposomal doxorubicin 59 refractory NSCLC 59 gemcitabine carboplatin 59 EGFR TKI 59 chronic myeloid 59 carcinoembryonic antigen 59 PIK3CA 59 RNase L 59 haematopoietic 59 thromboxane A2 59 vinorelbine tartrate 59 cytolytic 59 castrate resistant prostate cancer 59 progesterone receptor negative 59 HER2 positive metastatic breast 59 Vidaza azacitidine 59 tyrosine kinase inhibitor 59 breast carcinomas 59 MAGE A3 59 VEGF receptor 59 FUSILEV enhances 59 refractory gastrointestinal stromal 59 EpCAM 59 myeloproliferative diseases 59 metastatic androgen independent 59 somatostatin receptors 59 ceftazidime 59 radiosensitivity 59 alpha#beta# 59 recurrent metastatic 59 pancreatic colon 59 Azacitidine 59 Epidermal growth 59 Smac mimetic 59 CagA 59 adenoviral 59 myeloid 59 Multiple Myeloma MM 59 nilotinib Tasigna 59 TNF Blockers 59 indinavir Crixivan 59 KRAS oncogene 59 mineralocorticoid 59 refractory cutaneous T 59 histologies 59 Xanafide 59 skeletal metastases 59 tumoral 59 Mg Uk 59 hypoxia inducible factor 59 unresectable inoperable 59 resistant hormone refractory 59 AMACR 59 agonistic human 59 gastrointestinal stromal tumor 59 IMA# 59 potent inducer 59 EGFR mutation positive 59 ADP receptor antagonist 59 gastrointestinal stromal tumor GIST 59 PEGylated anti 59 Vidaza R 59 metastatic pancreatic 59 Epstein Barr Virus EBV 59 xenograft models 59 colorectal gastric 59 factor receptor EGFR 59 T1c 59 ovarian pancreatic 58 cytotoxic T lymphocyte 58 colorectal adenocarcinoma 58 sarcomatoid 58 c MYC 58 uveal melanoma 58 TNF Tumor Necrosis Factor 58 c myc 58 plasmacytoid 58 5 HT4 58 gastrointestinal stromal tumors GIST 58 ADAMTS# 58 ribonucleotide reductase clinically validated 58 #T# tumor 58 breast carcinoma 58 non mutated KRAS 58 deCODE AF TM 58 HCV polymerase 58 5 FU leucovorin 58 Amgen Neulasta R 58 constitutively expressed 58 gastrointestinal tumors GIST 58 Elotuzumab 58 cervix colon 58 Cyclooxygenase 2 58 NMDA N 58 ERK signaling 58 EGFr expressing metastatic colorectal 58 cytologically confirmed 58 retinoic acid receptor 58 MDA MB 58 leiomyoma 58 binds selectively 58 Î ² 58 castrate resistant 58 acadesine 58 paragangliomas 58 androgen independent 58 lexidronam injection 58 demonstrated antitumor activity 58 TNFα 58 GSTP1 58 WT1 58 epithelial ovarian 58 polycythemia vera essential thrombocythemia 58 mitogenic 58 mutational status 58 pregnancy bacterial vaginosis 58 transthyretin amyloidosis 58 mitogen activated protein kinase 58 advanced unresectable 58 EGFR activating mutations 58 Heterozygous 58 Immunomodulatory 58 Systemic lupus erythematosus SLE 58 humanized monoclonal antibodies 58 lysyl oxidase 58 actinic keratosis AK 58 nasopharyngeal carcinoma 58 iNOS 58 adhesion molecule EpCAM expressing 58 non squamous 58 oligodendrogliomas 58 #p# [003] 58 carcinoids 58 CD# antibody [001] 58 5alpha reductase 58 docetaxel Taxotere ® 58 chemokine receptor 58 receptor inhibitor 58 TRAIL R1 58 Survivin 58 pulmonary metastases 58 neovasculature 58 adrenoceptor 58 haematologic 58 SPINK1 58 TrkA 58 PDGF receptor 58 inducible nitric oxide synthase 58 CDK inhibitor 58 VIPR2 58 heparanase 58 #I TM# 58 SSc 58 oral prodrug 58 Novel Oral 58 myeloproliferative disorders 58 investigational oral inhibitor 58 fibrosarcoma 58 adalimumab Humira 58 cell lymphoma CTCL 58 stage IIIb IV 58 thyroid hormone receptor 58 constitutively active 58 MET amplification 58 metastatic bladder 58 mTOR inhibitors 58 autocrine 58 C5aR 58 Trichophyton rubrum 58 activin 58 p# MAPK 58 Vandetanib 58 leukemia CLL 58 BRAF mutant 58 vinca alkaloids 58 sunitinib Sutent 58 p# p# 58 VEGFR 58 Ceflatonin 58 Mutational 58 Carcinoid tumors 58 enkephalin 58 erlotinib Tarceva 58 cervical breast 58 Quinamed 58 HER1 58 EGFRvIII 58 TNFalpha 58 assay detects 58 immunoreactivity 58 tumor subtypes 58 adenocarcinomas 58 fallopian tube cancers 58 CpG island 58 pancreatic endocrine 58 arthritis PsA 58 relapsed refractory multiple myeloma 58 thyroid carcinoma 58 relapsing remitting MS RRMS 58 pro angiogenic 58 UGT#A# 58 5 HT6 receptor 58 constitutively activated 58 malignant prostate 58 hA# 58 metaplasia 58 antibody MT# 58 Irinotecan 58 sorafenib Nexavar 58 serine threonine 58 medically inoperable 58 squamous 58 survivin 58 J. Clin 58 Aviptadil 58 metastatic renal cell carcinoma 58 desmoplastic 58 NTDDS 58 peptide antigens 58 intraperitoneally 58 ALN HPN 58 interferon γ 58 TOP2A 58 EGF receptors 58 co stimulatory molecules 58 Annamycin 58 HER2/neu 58 cell acute lymphoblastic 58 lactate dehydrogenase LDH 58 TIMP 1 57 prostanoid 57 radiosensitive 57 nilotinib Tasigna ® 57 5 hydroxytryptamine 57 pituitary adenomas 57 hepatitis C HCV 57 gastric carcinoma 57 luteinizing hormone releasing 57 ALK inhibitor 57 humanized interleukin 6 57 SNP rs# [001] 57 antiproliferative activity 57 EGFR protein 57 LymphoStat B belimumab 57 ANCA associated 57 alkylating agent 57 acid phosphatase PAP 57 Angiotensin converting enzyme 57 breast pancreatic 57 HepG2 cells 57 includes S. anginosus 57 cyclophosphamide methotrexate 57 cholesteryl ester transfer 57 Carcinomas 57 OMP #R# 57 Atypical Hemolytic Uremic Syndrome 57 Pralatrexate 57 Proc Am Soc 57 imatinib Gleevec 57 CDK4 57 investigational immunotherapy 57 PDGFRA 57 Lenalidomide 57 Aromatase 57 methylenetetrahydrofolate reductase 57 reversible inhibitor 57 PNET 57 TTR amyloidosis 57 Kinoid 57 refractory anemia RA 57 signal transduction inhibitors 57 mucinous 57 Myeloid 57 Paraplatin ® 57 tumor antigen 57 KRAS mutation 57 myocardial infarction ventricular fibrillation 57 bullous 57 leiomyomas 57 Platinol ® cisplatin 57 hepatocellular carcinomas 57 HuLuc# 57 ovarian carcinoma 57 dopamine D2 57 MALT lymphoma 57 proto oncogene 57 cMET 57 submandibular 57 nodal metastasis 57 Plasmid DNA 57 pancreatic carcinoma 57 PAR1 57 Epigenomics proprietary 57 pediatric acute lymphoblastic 57 novel immunotherapeutic 57 radiotherapeutic 57 VEGFR1 57 Personalized Immunotherapy 57 multikinase inhibitor 57 refractory metastatic 57 mediated inhibition 57 refractory multiple myeloma 57 squamous cell lung cancer 57 Cytomegalovirus CMV 57 chemotherapy cisplatin 57 PC# cells 57 cytokeratin 57 bispecific 57 colorectal ovarian 57 K ras 57 HERCEPTIN 57 HDAC enzymes 57 virus HCV protease inhibitor 57 Taxotere ® 57 glycopeptide 57 S. intermedius 57 AGTR1 57 beta2 57 products MKC# PP 57 hepatocellular cancer 57 Apaziquone 57 Th2 cytokines 57 completely resected 57 SCCHN 57 biologic DMARD 57 GISTs 57 CD3 + 57 Autoantibodies 57 Orally administered 57 histologic subtype 57 novel histone deacetylase 57 hTERT 57 potently inhibit 57 variant allele 57 A1PI 57 Mucosal 57 chemopreventive agent 57 sphingosine 1 57 small lymphocytic lymphoma 57 gemcitabine Gemzar 57 plasmid encoding 57 JAK2 V#F 57 paclitaxel cisplatin 57 CDKN2A 57 thymoma 57 J Allergy Clin 57 diagnostic biomarker 57 CD#c 57 Luteinizing Hormone Releasing Hormone 57 HGS ETR2 57 KRAS mutated 57 renal fibrosis 57 NASH Huntington 57 reversible inhibitors 57 Omacetaxine 57 CD# molecule 57 pancreatic lung 57 antifibrotic 57 PLX STROKE targeting 57 p#NTR 57 gastrointestinal stromal tumors 57 lung ovary 57 pheochromocytomas 57 Intravenous Human 57 Paraplatin ® carboplatin 57 chemosensitizer 57 Escherichia coli Klebsiella pneumoniae 57 ductal carcinomas 57 FGFR2 57 Genotyping Test 57 pancreatic islet cell 57 IGF1R 57 localized renal 57 neuroblastoma tumors 57 non metastatic resectable 57 indolent follicular non 57 BCG refractory 57 selective antagonist 57 HBsAg 57 thymic carcinoma 57 Proxinium TM 57 cytopathic 57 selective agonist 57 protein tyrosine phosphatase 57 TGF β 57 hepatocellular carcinoma HCC 57 humanized anti 57 CLL SLL 57 progesterone receptor PR 57 Clusterin 57 MMP9 57 paraganglioma 57 folate receptor 57 basal cell skin 57 carboxyl terminal 57 messenger ribonucleic acid 57 IFN γ 57 microdeletions 57 follicular lymphoma FL 57 NPC 1C 57 KSP inhibitor 57 gastric adenocarcinoma 57 Antigenics QS 57 CTAP# Capsules 57 tryptase 56 Fibroblast Growth Factor Receptor 56 ERalpha 56 Tofacitinib 56 acinar 56 ara C 56 tipranavir ritonavir 56 lymphoid cells 56 hyperplastic 56 cancer mCRC 56 metalloproteinase 56 bladder ovarian 56 intraepithelial neoplasia 56 granulosa cell 56 Her-2/neu 56 cause cardiac channelopathies 56 epithelioid 56 Gorlin syndrome 56 BCR ABL 56 immunostaining 56 iobenguane 56 thyroid peroxidase 56 Her2 positive 56 anti PlGF 56 EGFR pathway 56 SensoLyte ® 56 Gefitinib 56 Surgical resection 56 cetuximab Erbitux ® 56 Cloretazine 56 CDH1 56 Intravenous immunoglobulin 56 HIV HCV coinfected 56 GNAQ 56 hormone refractory metastatic prostate 56 colorectal pancreatic 56 mouse xenograft models 56 alvespimycin 56 potent CYP#A# inhibitors 56 receptor inhibiting monoclonal 56 promoter methylation 56 predominantly classic subfoveal 56 KIF6 gene 56 sodium thiosulfate STS 56 Alferon LDO 56 metastatic CRC 56 tumor specific antigen 56 AML MDS 56 CREBBP 56 ovarian carcinomas 56 inhibit replication 56 HGPIN 56 chemo resistant 56 paclitaxel Taxol 56 Polymorphisms 56 leukemia AML 56 RhuDex R 56 Sapacitabine 56 para aortic 56 Glioblastoma Multiforme 56 HyperAcute 56 germline mutation 56 radiolabeled TM# 56 unresectable tumors 56 SIR Spheres 56 alkylating 56 UPLYSO 56 recombinant fusion 56 FasL 56 papillary thyroid carcinoma 56 NS#/#A protease 56 interferon lambda 56 underwent surgical resection 56 florbetaben 56 selectively inhibit 56 NS4A 56 mouse mammary tumor 56 N cadherin 56 denileukin diftitox 56 alfa 2a 56 MGd 56 PSMA ADC 56 CIN2 + 56 calcium calmodulin dependent 56 annexin 56 Factor VIIa 56 corticosteroid dexamethasone 56 MTHFR 56 EGFR inhibitors 56 cyclin dependent kinase 56 situ CIS 56 subcutaneous immunoglobulin 56 Camptosar ® 56 lysophosphatidic acid LPA 56 PNP inhibitor 56 liver cancers TTR 56 minimally symptomatic 56 uPAR 56 recombinant adeno associated 56 Streptococcus agalactiae 56 receptor blocker 56 antitumor effect 56 vWD 56 aurora kinase 56 related apoptosis inducing 56 Pericardial 56 untreated metastatic melanoma 56 pyrimidine 56 B7 H3 56 Chronic Myelogenous Leukemia 56 endocrine therapies 56 Idiopathic Pulmonary Fibrosis 56 breast cancer subtypes 56 VP# [004] 56 anaplastic lymphoma kinase 56 Prolongs Survival 56 pertuzumab 56 chemoresistant 56 ADPKD 56 estramustine 56 liposomal doxorubicin 56 pancreatic ovarian 56 COL#A# 56 HER2 negative 56 eIF 4E 56 BRAF mutation 56 oncolytic 56 phosphoprotein 56 urothelial bladder cancer 56 Oncolytic 56 transmembrane receptor 56 inhibit EGFR 56 multicentric 56 cyclin E 56 relapsed leukemia 56 Metastatic colorectal cancer 56 unknown etiology 56 formerly LymphoStat B 56 malignant pancreatic 56 Metastases 56 Metastatic breast cancer 56 uterine cervical 56 factor G CSF 56 Adenoma 56 Human papillomavirus 56 refractory colorectal cancer 56 aT cell 56 lymphoid organs 56 IL 1ß 56 unresectable stage 56 novel tubulin binding 56 upregulates 56 interferon pathway 56 PTPN# 56 alpha1 antitrypsin deficiency 56 glutamic acid decarboxylase 56 xenografts 56 refractory acute myeloid 56 Selective Internal 56 TLR antagonist 56 huN# DM1 55 malignant cancerous 55 epirubicin 55 irinotecan doxorubicin oxaliplatin paclitaxel 55 anaplastic astrocytoma AA 55 Systemic Sclerosis 55 schwannomas 55 generation antisense inhibitor 55 Stage IIIb 55 xenograft tumors 55 depsipeptide 55 FGFR1 55 BCR ABL protein 55 hENT1 55 Viread tenofovir disoproxil fumarate 55 CCL# 55 mutated KRAS gene 55 renal carcinoma 55 ovarian lung 55 bendamustine HCl 55 ERa 55 ARRY # 55 lymphocytosis 55 hematopoietic cell 55 alveolar epithelial cells 55 DNA intercalator 55 peritoneal carcinomatosis 55 NY ESO 55 Glioblastoma multiforme GBM 55 IDH1 mutation 55 non nucleoside inhibitor 55 monocytic 55 Ibritumomab Tiuxetan 55 apolipoprotein E4 55 cutaneous T cell 55 phosphorylates 55 predictive biomarker 55 imetelstat 55 rs# [004] 55 tubulin polymerization 55 CTAP# 55 infliximab monotherapy 55 underlying vasculopathy 55 Bortezomib 55 xenograft model 55 ovarian endometrial 55 N. gonorrhoeae 55 NKG2D 55 sodium glucose cotransporter 55 Vicinium TM 55 pT2 55 esophageal carcinoma 55 ErbB 55 microvascular endothelial cells 55 systemic ALCL 55 events thrombocytopenia neutropenia 55 L#R 55 hormone LHRH antagonist 55 stage IIIB 55 superficial bladder cancer 55 FOLFIRI alone 55 chronic HBV 55 T#M 55 receptor CXCR4 55 T#I mutant 55 Eg5 55 PROMUS TM 55 decarboxylase 55 colorectum 55 EGFR mutation 55 adefovir dipivoxil 55 sunitinib malate 55 cytoprotective 55 heavily pretreated 55 medullary thyroid cancer 55 B CLL 55 cutaneous melanoma 55 palliative radiotherapy 55 myeloperoxidase 55 basophils 55 HER2/neu gene 55 hypercholesterolemia liver 55 methylated DNA 55 ovarian colon 55 selective inhibitor 55 hCG beta 55 chromosome #q# [002] 55 CCR5 delta# 55 Severe Sepsis 55 prognostic marker 55 c Src 55 Epstein Barr virus EBV 55 bevacizumab Avastin ® 55 nonsmall cell lung cancer 55 activated lymphocytes 55 Parathyroid Hormone 55 arteriovenous malformations